MedPath

MRgLITT for mTLE: A PROBE Trial

Not Applicable
Recruiting
Conditions
Temporal Lobe Epilepsy (TLE)
Registration Number
NCT06720922
Lead Sponsor
Beijing Tiantan Hospital
Brief Summary

How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?

Detailed Description

1. Compare the clinical prognosis between magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) and traditional open surgery (OS) on patients with mesial temporal lobe epilepsy (mTLE).

2. Explore the factors associated with seizure outcomes.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
240
Inclusion Criteria
  • 18-65 years.
  • Drug-resistant mesial temporal lobe epilepsy.
  • Seizure frequency ≥ 1 time /month.
  • Participants approved.
Exclusion Criteria
  • History of brain surgery.
  • Intracranial space occupying lesions.
  • Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Seizure freedom rate6-month, 1-year after surgery

According to International League Against Epilepsy \[ILAE\] Outcome Scale

Secondary Outcome Measures
NameTimeMethod
Seizure frequency6-month, 1-year after surgery

Times/Months

Seizure severity6-month, 1-year after surgery

National Hospital Seizure Severity Scale (NHS3)

Cognitive function evaluation6-month, 1-year after surgery

Multiple Ability Self-Report Questionnaire (MASQ)

Memory function evaluation6-month, 1-year after surgery

Multifactorial Memory Questionnaire (MMQ)

Quality of life for epilepsy patients6-month, 1-year after surgery

EQ-5D-5L

Adverse eventswithin 7 days, 6-month, 1-year after surgery

percentage

Severe adverse eventswithin 7 days, 6-month, 1-year after surgery

percentage

Length of hospital stayafter surgery

days

Rate of antiepileptic drug reduction or withdrawn1-year after surgery

percentage

Rate of reoperations1-year after surgery

percentage

Trial Locations

Locations (1)

Beijing Tiantan Hospital

🇨🇳

Beijing, Beijing, China

Beijing Tiantan Hospital
🇨🇳Beijing, Beijing, China
Jiajie Mo, Dr.
Contact
86 01059975051
jiajiemo@foxmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.